Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
16.39B
Market cap16.39B
Price-Earnings ratio
18.05
Price-Earnings ratio18.05
Dividend yield
Dividend yield
Average volume
423.97K
Average volume423.97K
High today
High today
Low today
Low today
Open price
$249.62
Open price$249.62
Volume
0.00
Volume0.00
52 Week high
$282.15
52 Week high$282.15
52 Week low
$186.05
52 Week low$186.05

Stock Snapshot

Ascendis Pharma A/S(ASND) stock is priced at $249.36, giving the company a market capitalization of 16.39B. It carries a P/E multiple of 18.05.

On 2026-08-28, Ascendis Pharma A/S(ASND) shares started trading at $249.62, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 423.97K.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $186.05.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $186.05.

ASND News

Simply Wall St 10h
Ascendis Pharma Shares Week 104 Data As FDA Clears Pediatric Achondroplasia Drug

Ascendis Pharma (NasdaqGS:ASND) presents Week 104 pivotal data on TransCon CNP (navepegritide) in achondroplasia at ISDS 2026, highlighting durable clinical out...

Ascendis Pharma Shares Week 104 Data As FDA Clears Pediatric Achondroplasia Drug
TipRanks 1d
Ascendis Pharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Ascendis Pharma (ASND) with a Buy rating and $345 price target The firm believes the shares at current levels are underpri...

TipRanks 3d
Ascendis Pharma Earnings Call Highlights Blockbuster Momentum

Ascendis Pharma A/S ((ASND)) has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks Unlock powerful in...

Analyst ratings

100%

of 22 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.